Biogen Idec gains commercial rights of Tysabri from Elan
Posted: Thu Apr 04, 2013 12:27 am
Biogen Idec gains commercial rights of Tysabri from Elan Corporation
Biogen Idec has completed its purchase of Elan Corporation’s interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights of Tysabri. The transaction was originally announced on February 6, 2013....................Read More - http://www.ms-uk.org/index.cfm/tysabri
Biogen Idec has completed its purchase of Elan Corporation’s interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights of Tysabri. The transaction was originally announced on February 6, 2013....................Read More - http://www.ms-uk.org/index.cfm/tysabri